Janux Therapeutics

Janux Therapeutics is a clinical-stage biopharmaceutical company located in San Diego, California. Founded in June 2017, the company is dedicated to developing innovative immunotherapies aimed at treating cancer. Its mission focuses on creating tumor-specific immune responses that effectively target and eliminate tumors while preserving healthy tissue. The company specializes in unique T cell immunotherapies, utilizing its proprietary Tumor Activated T Cell Engager (TRACTr) platform. This technology selectively modulates T cells within the tumor microenvironment, enhancing the immune system's ability to combat cancer with reduced safety concerns. Janux is advancing its lead program in prostate cancer through clinical trials, which began in the second half of 2022. Janux Therapeutics is committed to serving cancer patients by providing safe and effective treatments. The company fosters a collaborative culture that encourages scientific innovation and data-driven decision-making, potentially leading to future partnerships with other biotech firms or research institutions.